Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15797MR)

This product GTTS-WQ15797MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15797MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8214MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ12634MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ11443MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ11939MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ4862MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ849MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ12345MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ9572MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW